期刊文献+

聚乙二醇干扰素治疗慢性丙型肝炎有效性的Meta分析 预览 被引量:4

Meta-analysis of the Effectiveness on Peginterferon for Chronic Hepatitis C
在线阅读 免费下载
收藏 分享 导出
摘要 目的:系统评价聚乙二醇干扰素基于中国人群治疗慢性丙型肝炎的有效性。方法:检索数据库2004~2014年公开发表的聚乙二醇干扰素治疗慢性丙型肝炎的国内临床试验,以患者持续病毒学应答(SVR)获得率作为临床结果指标进行Meta分析。结果:观察组与对照组SVR获得率有显著差异,其中聚乙二醇干扰素α-2a组SVR获得率有显著差异,聚乙二醇干扰素α-2b组SVR获得率无显著差异。结论:聚乙二醇干扰素可以显著提高中国慢性丙型肝炎患者SVR获得率。其中聚乙二醇干扰素α-2a更具有效性,但聚乙二醇干扰素α-2b安全性更高。 Objective: To systematically evaluate the clinical efficacy of peginterferon for Chinese chronic hepatitis C patients. Methods: The domestic chronic hepatitis C clinical trials adopting peginterferon published from 2004 to 2014 were retrieved, and SVR a- chieving rate was considered as clinical effective index to develop a Meta-analysis. Results: The SVR achieving rate between experimental group and control group was statistically different, among which the SVR achieving rate of the group adopting peginterferon α-2a was statis- tically different while the group adopting peginterferon α-2b was not. Conclusion: Peginterferon greatly improves the SVR achieving rate for Chinese chronic hepatitis C patients. Furthermore,peginterferon α-2a shows better clinical effect and peginterferon α-2b shows better safety.
作者 陈平钰 马爱霞 CHEN Ping-yu, MA Ai-xia ( School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu Nanjing 211198, China)
出处 《中国药物评价》 2014年第6期345-349,355共6页 Chinese Journal of Drug Evaluation
关键词 聚乙二醇干扰素 慢性丙型肝炎 META分析 Peginterferon Chronic hepatitis C Meta-analysis
作者简介 陈平钰,女,硕士研究生,研究方向:药物经济学。E-mail:chenpingyu220@163.com [通讯作者]马爱霞,女,博士,教授,博士生导师,研究方向:药物经济学与医药产业政策研究。E-mail:ma86128@sina.com
  • 相关文献

参考文献22

二级参考文献96

共引文献165

同被引文献49

  • 1华瑞,牛俊奇.聚乙二醇化干扰素——抗丙型肝炎病毒的最佳选择[J].临床肝胆病杂志,2004,20(4):253-254. 被引量:5
  • 2陈秋霞,黄云川.厦门市同安区1992~2003年病毒性肝炎疫情资料分析[J].预防医学论坛,2005,11(6):719-720. 被引量:3
  • 3金若珏,王晓东,陈永平.聚乙二醇化干扰素a-2b联合利巴韦林治疗慢性丙型肝炎的疗效和安全性的研究[J].实用临床医学(江西),2007,8(8):37-38. 被引量:4
  • 4Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014, 61(1 Suppl): S45-S57. 被引量:1
  • 5Nettels RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virusgenotype 1 [J]. Hepatology, 2011, 54(6): 1956-1965. 被引量:1
  • 6Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trails: is blinding necessary? [J]. Control Clin Trials, 1996, 17(1): 1-12. 被引量:1
  • 7Hezode C, Hirschfield GM, Ghesquiere Wj et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study[J]. Gut, 2015, 64(6): 948-956. 被引量:1
  • 8Dore GJ, Lawitz E, Hezode C, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection[J]. Gastroenterology, 2015, 148(2): 355-366. 被引量:1
  • 9Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasivir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection[J]. Antivir Ther, 2014, 19(5): 491-499. 被引量:1
  • 10Izumi N, Yokosuka O, Kawada N, et al. Daclatasivir combined with peginterferon alfa-2b and ribavirin in Japanese patient infected with hepatitis C genotype 1 [J]. Antivir Ther, 2014, 19(5): 501-510. 被引量:1

引证文献4

二级引证文献6

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈